Ian C. Read
58 Chairman and Chief Executive Officer since December 2011. President and
Chief Executive Officer from December 2010 until December 2011. Senior Vice
President, Group President of the Worldwide Biopharmaceutical Businesses (Primary
Care, Specialty Care, Oncology, Established Products and Emerging Markets),
from 2006 through December 2010. Since joining Pfizer in 1978 as an operational
auditor,
Mr. Read has held various positions of increasing responsibility in pharmaceutical
operations. He worked in Latin America through 1995, holding positions including
Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil.
In 1996, Mr. Read was appointed President of Pfizer’s International Pharmaceuticals
Group, with responsibility for Latin America and Canada. He became Executive
Vice President, Europe in 2000, was named a Corporate Vice President in 2001,
and assumed responsibility for Canada, in addition to Europe, in 2002.
Mr. Read later became accountable for operations in both the Africa/Middle East
region and Latin America as well. Currently a Director of Kimberly-Clark Corporation.
Serves on the Boards of Pharmaceutical Research and Manufacturers of America
(PhRMA), the European Federation of Pharmaceutical Industries and Associations,
and the Partnership for New York City. Our Director since December 2010 and
Chair of our Board’s Executive Committee.
Olivier Brandicourt
56 President and General Manager of Pfizer Primary Care since 2009. In early
2009, served as President and General Manager of Pfizer Specialty Care. Senior
Vice President and General Manager of U.S. Pratt Business Unit from 2007 until
2008. Managing Director of the United Kingdom/Ireland Pfizer subsidiary from
2004 to 2007.
Frank A. D’Amelio
54 Executive Vice President, Business Operations and Chief Financial Officer
since December 2010. Senior Vice President and Chief Financial Officer from
September 2007 until December 2010. Prior to joining Pfizer he was Senior Executive
Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent
from November 2006 until August 2007. Chief Operating Officer of Lucent Technologies
from January 2006 until November 2006. Director of Humana, Inc. and Chair of
the Humana Audit Committee. He is a Director of the Independent College Fund
of New Jersey.
Mikael Dolsten
53 President of Worldwide Research and Development since December 2010. Senior
Vice President; President of Worldwide Research and Development from May 2010
until December 2010. Senior Vice President; President of Pfizer BioTherapeutics
Research & Development Group from October 2009 until May 2010. He was Senior
Vice President of Wyeth and President, Wyeth Research from June 2008 until October
2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January
2008 until June 2008. Dr. Dolsten was Global Head, Corporate Division Pharma
Research and Discovery, of Boehringer Ingelheim Corporation from 2003 to 2007.
Geno J. Germano
51 President and General Manager, Pfizer Specialty Care and Oncology since
December 2010. President and General Manager, Specialty Care from October 2009
until December 2010. President, U.S. Pharmaceuticals and Women’s Health
Care Unit, Wyeth Pharmaceuticals from 2008 through October 2009. President and
General Manager, U.S. Pharmaceutical Business Unit, Wyeth Pharmaceuticals from
2007 through 2008. Executive Vice President and General Manager, Pharmaceutical
Business Unit, Wyeth Pharmaceuticals from 2004 through 2007. Member of the Board
of Trustees for Albany College of Pharmacy and Member of the Board of Directors
of BIO – Biotechnology Industry Organization.
Charles H. Hill III
56 Executive Vice President, Worldwide Human Resources since December 2010.
Senior Vice President, Human Resources for Worldwide Biopharmaceuticals Businesses
from 2008 through December 2010. Vice President, Human Resources, Worldwide
Pharmaceutical Operations from 2004 through 2008.
Douglas M. Lankler
46 Executive Vice President, Chief Compliance and Risk Officer since February
2011. Executive Vice President, Chief Compliance Officer from December 2010
until February 2011. Senior Vice President and Chief Compliance Officer from
January 2010 until December 2010. Senior Vice President, Deputy General Counsel
and Chief Compliance Officer from August 2009 until January 2010. Senior Vice
President, Associate General Counsel and Chief Compliance Officer from October
2006 until August 2009. Prior to October 2006, Mr. Lankler held various positions
of increasing responsibility within the Pfizer Legal Division.
Freda C. Lewis-Hall
57 Executive Vice President, Chief Medical Officer since December 2010. Senior
Vice President, Chief Medical Officer from May 2009 until December 2010. Previously,
she was Chief Medical Officer and Executive Vice President, Medicines Development
at Vertex Pharmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was
Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers
Squibb Company from 2003 until May 2008.
Kristin C. Peck
40 Executive Vice President, Worldwide Business Development and Innovation
since December 2010. Senior Vice President, Worldwide Business Development,
Strategy and Innovation from April 2010 until December 2010. Senior Vice President,
Worldwide Strategy and Innovation from 2008 until April 2010. Vice President,
Strategic Planning, from 2007 to 2008. Chief of Staff to the Vice Chairman from
2006 to 2007 and Senior Director, Strategic Planning from 2004 to 2006.
Cavan M. Redmond
51 Group President, Animal Health, Consumer Healthcare and Corporate Strategy
since August 2011. Group President, Animal Health, Consumer Healthcare, Capsugel
and Corporate Strategy from December 2010 until August 2011. Senior Vice President;
Group President, Pfizer Diversified Businesses from October 2009 until December
2010. President, Wyeth Consumer Healthcare and Animal Health Business from May
2009 until October 2009. President, Wyeth Consumer Healthcare from December
2007 until May 2009. Executive Vice President and General Manager, BioPharma,
Wyeth Pharmaceuticals from 2003 until December 2007.
Amy W. Schulman
51 Executive Vice President and General Counsel; President and General Manager,
Nutrition since December 2010. Senior Vice President and General Counsel from
June 2008 until December 2010. Ms. Schulman was a partner at the law firm of
DLA Piper from 1997 until joining Pfizer in June 2008. Member of the Board of
Directors of Wesleyan University and the Brooklyn Academy of Music.
David S. Simmons
47 President and General Manager, Emerging Markets and Established Products
units since December 2010. President and General Manager, Established Products
from 2008 until December 2010. Since joining Pfizer in 1996, Mr. Simmons has
held various positions of increasing responsibility in pharmaceutical operations,
including Regional President, Central Southern Europe; Vice President of Marketing,
Pfizer Canada; and Country Manager, Pfizer Greece. He is a member of the U.S.-Russia
Business Council and a Trustee of The Linsly School.
Sally Susman
50 Executive Vice President, Policy, External Affairs and Communications of
Pfizer since December 2010. Senior Vice President, Policy, External Affairs
and Communications from December 2009 until December 2010. Senior Vice President
and Chief Communications Officer from February 2008 until December 2009. Prior
to joining Pfizer, Ms. Susman held senior level positions at The Estee Lauder
Companies, including Executive Vice President from 2004 to January 2008.
Pfizer Inc currently has 79000 employees.